tetano
Editor, Senior Moderator
Rev Esp Cardiol. 2020 Apr 22.
doi: 10.1016/j.recesp.2020.04.006. Online ahead of print.
[Recommendations on Antithrombotic Treatment During the COVID-19 Pandemic. Position Statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology]
[Article in Spanish]
David Vivas[SUP] 1 [/SUP], Vanessa Rold?n[SUP] 2 [/SUP], Mar?a Asunci?n Esteve-Pastor[SUP] 3 [/SUP], Inmaculada Rold?n[SUP] 4 [/SUP], Antonio Tello-Montoliu[SUP] 3 [/SUP], Juan Miguel Ruiz-Nodar[SUP] 5 [/SUP], Juan Cos?n-Sales[SUP] 6 7 [/SUP], Jos? Mar?a G?mez[SUP] 8 [/SUP], Luciano Consuegra[SUP] 9 [/SUP], Jos? Luis Ferreiro[SUP] 10 [/SUP], Francisco Mar?n[SUP] 3 [/SUP], Vicente Arrarte[SUP] 5 [/SUP], Manuel Anguita[SUP] 11 [/SUP], ?ngel Cequier[SUP] 10 [/SUP], Juli?n P?rez-Villacast?n[SUP] 1 [/SUP]
Affiliations
Abstract
The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.
doi: 10.1016/j.recesp.2020.04.006. Online ahead of print.
[Recommendations on Antithrombotic Treatment During the COVID-19 Pandemic. Position Statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology]
[Article in Spanish]
David Vivas[SUP] 1 [/SUP], Vanessa Rold?n[SUP] 2 [/SUP], Mar?a Asunci?n Esteve-Pastor[SUP] 3 [/SUP], Inmaculada Rold?n[SUP] 4 [/SUP], Antonio Tello-Montoliu[SUP] 3 [/SUP], Juan Miguel Ruiz-Nodar[SUP] 5 [/SUP], Juan Cos?n-Sales[SUP] 6 7 [/SUP], Jos? Mar?a G?mez[SUP] 8 [/SUP], Luciano Consuegra[SUP] 9 [/SUP], Jos? Luis Ferreiro[SUP] 10 [/SUP], Francisco Mar?n[SUP] 3 [/SUP], Vicente Arrarte[SUP] 5 [/SUP], Manuel Anguita[SUP] 11 [/SUP], ?ngel Cequier[SUP] 10 [/SUP], Juli?n P?rez-Villacast?n[SUP] 1 [/SUP]
Affiliations
- PMID: 32327870
- PMCID: PMC7176384
- DOI: 10.1016/j.recesp.2020.04.006
Abstract
The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.